What are the recent trends in market size and growth for the eosinophilic asthma market?
The eosinophilic asthma market size has grown rapidly in recent years. It will grow from $2.69 billion in 2024 to $3.17 billion in 2025 at a compound annual growth rate (CAGR) of 17.7%. The growth in the historic period can be attributed to increase in pollution, lower immunity in population, rise in prevalence of eosinophilic asthma, increase in prevalence of allergens and respiratory conditions, rise in healthcare expenditure, and rise in R&D activities.
The eosinophilic asthma market size is expected to see rapid growth in the next few years. It will grow to $6.01 billion in 2029 at a compound annual growth rate (CAGR) of 17.4%. The growth in the forecast period can be attributed to increasing prevalence of respiratory diseases, rising awareness and diagnosis rates, expanding therapeutic indications for monoclonal antibodies, growing investment in healthcare infrastructure, and the rising personalized medicine approaches. Major trends in the forecast period include development of targeted biologics, improved diagnostic tools, personalized treatment approaches, enhanced drug delivery systems, integration of digital health technologies, and expanded clinical trials for novel therapies.
Get Your Free Sample of The Global Eosinophilic Asthma Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21184&type=smp
How have varous drivers impacted the growth of the eosinophilic asthma market?
The rising smoking habits is expected to propel the growth of the eosinophilic asthma market going forward. Smoking habits refer to the regular behaviors or patterns of using tobacco products, such as the frequency, context, and duration of smoking, often influenced by psychological, social, and environmental factors. The rising smoking habits are due to factors such as increased stress levels, targeted marketing by tobacco companies, lack of awareness about health risks, and social acceptance of smoking in certain cultures. Eosinophilic asthma treatment helps reduce airway inflammation and improve lung function, which can encourage smoking cessation by alleviating the respiratory issues that often drive patients to continue smoking. For instance, in December 2023, according to the National Health Service, a UK-based government department, there were an estimated 408,700 hospital admissions due to smoking in 2022–23 from 389,800 in 2021–22, representing an increase of 4.8%. Therefore, the rising smoking rates drives the eosinophilic asthma market.
What are the primary segments of the eosinophilic asthma market?
The eosinophilic asthma market covered in this report is segmented –
1) By Disease: Severe Eoisnophilic Asthma, Mild To Moderate Eosinophilic Asthma
2) By Treatment: Biologics, Bronchodilators, Corticosteroids, Immunomodulators, Other Treatments
3) By End User: Hospitals, Clinics, Other End Users
Subsegments:
1) By Severe Eosinophilic Asthma: Refractory Eosinophilic Asthma, Late-Onset Eosinophilic Asthma
2) By Mild To Moderate Eosinophilic Asthma: Early-Onset Eosinophilic Asthma, Intermittent Eosinophilic Asthma
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/eosinophilic-asthma-global-market-report
Which firms are leading the eosinophilic asthma market?
Major companies operating in the eosinophilic asthma market are Roche Holding AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Limited, Boehringer Ingelheim GmbH, Regeneron Pharmaceuticals Inc., Chiesi Farmaceutici S.p.A.
How will industry trends affect the trajectory of the eosinophilic asthma market?
Major companies operating in the eosinophilic asthma market are developing innovative drugs, to target specific immune pathways, reduce inflammation, and improve patient outcomes through personalized treatment options. A monoclonal antibody is a type of laboratory-made molecule that can mimic the immune system’s ability to fight off harmful pathogens such as viruses and bacteria that are created through a process involving the fusion of a specific antibody-producing cell with a cancer cell, allowing the production of large quantities of identical antibodies. For instance, in August 2024, AstraZeneca plc, a UK-based biopharmaceutical company announced Fasenra approved by the China’s National Medical Products Association, a China-based government agency for the treatment of severe eosinophilic asthma. It is specifically indicated for patients with severe eosinophilic asthma, a condition characterized by high levels of eosinophils, which can lead to inflammation and worsening asthma symptoms. It is a monoclonal antibody that targets and depletes eosinophils through a unique mechanism. Fasenra enhances the immune system’s ability by binding to the IL-5 receptor on eosinophils, to reduce eosinophil levels in the blood and tissues. The dosing regimen involves an initial loading phase followed by maintenance doses. Patients usually receive injections every four weeks for the first three doses, followed by every eight weeks thereafter.
Which geographic trends are shaping the eosinophilic asthma market, and which region has the highest market share?
North America was the largest region in the eosinophilic asthma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the eosinophilic asthma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Eosinophilic Asthma Market Report 2025 Offer?
The eosinophilic asthma market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Eosinophilic asthma is a form of asthma where high eosinophil counts, a specific white blood cell type, cause airway inflammation. This condition results in severe symptoms such as breathing issues and recurring flare-ups, with limited effectiveness from standard treatments such as inhaled steroids.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21184
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
